Trials / Completed
CompletedNCT05285033
RW Effectiveness of Lurbinectedin in Extensive Stage SCLC
Real-world Effectiveness and Treatment Sequences in Patients With Extensive Stage SCLC Who Received Lurbinectedin as Part of the French Early Access Program (ATU).
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 312 (actual)
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
LURBICLIN cohort will describe the demographic and clinical characteristics of patients who received at least one dose of lurbinectedin as part of ATU program. LURBICLIN will evaluate effectiveness and safety of lurbinectedin in real-world conditions.
Detailed description
LURBICLIN cohort will describe the demographic and clinical characteristics of patients who received at least one dose of lurbinectedin as part of ATU program. LURBICLIN will evaluate overall survival, real world progression-free survival, best response and duration of treatment in patients with advanced, metastatic Small Cell Lung Cancer (SCLC) who received lurbinectedin as part of the French Early Access Program (ATU). Previous and subsequent treatments (treatment delivered immediately after treatment with lurbinectedin) will be recorded. Those outcomes will be correlated to clinical, pathological, and radiological characteristics of patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lurbinectedin | Patients who received at least one dose of treatment with lurbinectedin as part of the French Early Access Program (ATU program). |
Timeline
- Start date
- 2022-04-01
- Primary completion
- 2022-12-15
- Completion
- 2022-12-15
- First posted
- 2022-03-17
- Last updated
- 2023-01-06
Locations
2 sites across 1 country: France
Source: ClinicalTrials.gov record NCT05285033. Inclusion in this directory is not an endorsement.